314 related articles for article (PubMed ID: 24721791)
1. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Pérez-Galán P; Mora-Jensen H; Weniger MA; Shaffer AL; Rizzatti EG; Chapman CM; Mo CC; Stennett LS; Rader C; Liu P; Raghavachari N; Stetler-Stevenson M; Yuan C; Pittaluga S; Maric I; Dunleavy KM; Wilson WH; Staudt LM; Wiestner A
Blood; 2011 Jan; 117(2):542-52. PubMed ID: 20956803
[TBL] [Abstract][Full Text] [Related]
3. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
4. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
5. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
6. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
[TBL] [Abstract][Full Text] [Related]
7. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Weniger MA; Rizzatti EG; Pérez-Galán P; Liu D; Wang Q; Munson PJ; Raghavachari N; White T; Tweito MM; Dunleavy K; Ye Y; Wilson WH; Wiestner A
Clin Cancer Res; 2011 Aug; 17(15):5101-12. PubMed ID: 21712452
[TBL] [Abstract][Full Text] [Related]
8. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
[TBL] [Abstract][Full Text] [Related]
9. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
10. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
13. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Cosenza M; Civallero M; Pozzi S; Marcheselli L; Bari A; Sacchi S
Hematol Oncol; 2015 Dec; 33(4):166-75. PubMed ID: 25394177
[TBL] [Abstract][Full Text] [Related]
14. PRDM1 is required for mantle cell lymphoma response to bortezomib.
Desai S; Maurin M; Smith MA; Bolick SC; Dessureault S; Tao J; Sotomayor E; Wright KL
Mol Cancer Res; 2010 Jun; 8(6):907-18. PubMed ID: 20530581
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
19. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]